{"id":298,"date":"2024-12-06T10:18:26","date_gmt":"2024-12-06T18:18:26","guid":{"rendered":"https:\/\/www.adarx.com\/?page_id=298"},"modified":"2026-09-15T13:18:08","modified_gmt":"2026-09-15T20:18:08","slug":"home","status":"publish","type":"page","link":"https:\/\/www.adarx.com\/dev\/","title":{"rendered":"Home"},"content":{"rendered":"\n
\n
\n

Amplifying Science<\/h2>\n\n\n\n
\n
\n

Leveraging our decades of siRNA drug development experience and proprietary technologies, we are focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Learn more about our next-generation research technologies.<\/p>\n<\/div>\n\n\n\n

\n
\"home-science-img-v2\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
Our Technology<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Patient Focused<\/h2>\n\n\n\n
\n
\n

Our goal is to control the expression of specific disease drivers with highly selective siRNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Learn about our ongoing clinical trials.<\/p>\n<\/div>\n\n\n\n

\n
\"home-patient-img\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
Patients Overview<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n\n\n\n
\n
\n

Robust Pipeline<\/h2>\n\n\n\n

We are advancing a robust pipeline of differentiated siRNA therapeutic candidates designed to deliver deep and durable reduction of target proteins with significant potential impact on disease burden, coupled with infrequent dosing. Learn more about our pipeline.<\/p>\n\n\n\n

\n
Pipeline<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\"home-pipeline-img\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n<\/div><\/div><\/div>\n\n\n\n
\n
\n

Collaborative Culture<\/strong><\/h2>\n

We are a team united by a shared vision to build a leading next-generation siRNA company. We are driven by innovation, excellence, respect, collaboration and integrity\u2014underpinned by our unwavering commitment to creating life-changing therapeutics for patients. Learn more about life at ADARx and how you can join our team.<\/p>\n

\n
Careers<\/a><\/div>\n<\/div>\n<\/div>\n
\n
\"home-culture-img-v2\"<\/figure>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n

News<\/h2>\n\n\n

September 24, 2026<\/p>

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering<\/h3><\/a><\/div><\/div>

August 24, 2026<\/p>

ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE<\/h3><\/a><\/div><\/div>

August 12, 2026<\/p>

ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments<\/h3><\/a><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

Amplifying Science Leveraging our decades of siRNA drug development experience and proprietary technologies, we are focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Learn more about our next-generation research technologies. Patient Focused Our goal is to control the expression of specific disease drivers with highly selective siRNA targeted therapies, […]<\/p>\n","protected":false},"author":1,"featured_media":392,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/home.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-298","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nHome - ADARx Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Home - ADARx Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Amplifying Science Leveraging our decades of siRNA drug development experience and proprietary technologies, we are focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Learn more about our next-generation research technologies. Patient Focused Our goal is to control the expression of specific disease drivers with highly selective siRNA targeted therapies, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adarx.com\/dev\/\" \/>\n<meta property=\"og:site_name\" content=\"ADARx Pharmaceuticals\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-15T20:18:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/home-bkg.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3840\" \/>\n\t<meta property=\"og:image:height\" content=\"1608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"name\":\"Home - ADARx Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/home-bkg.jpg\",\"datePublished\":\"2024-12-06T18:18:26+00:00\",\"dateModified\":\"2026-09-15T20:18:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/home-bkg.jpg\",\"contentUrl\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/home-bkg.jpg\",\"width\":3840,\"height\":1608,\"caption\":\"home-bkg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"name\":\"ADARx Pharmaceuticals\",\"description\":\"Providing hope for patients with intractable disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Home - ADARx Pharmaceuticals","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Home - ADARx Pharmaceuticals","og_description":"Amplifying Science Leveraging our decades of siRNA drug development experience and proprietary technologies, we are focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Learn more about our next-generation research technologies. Patient Focused Our goal is to control the expression of specific disease drivers with highly selective siRNA targeted therapies, […]","og_url":"https:\/\/www.adarx.com\/dev\/","og_site_name":"ADARx Pharmaceuticals","article_modified_time":"2026-09-15T20:18:08+00:00","og_image":[{"width":3840,"height":1608,"url":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/home-bkg.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adarx.com\/dev\/","url":"https:\/\/www.adarx.com\/dev\/","name":"Home - ADARx Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.adarx.com\/dev\/#primaryimage"},"image":{"@id":"https:\/\/www.adarx.com\/dev\/#primaryimage"},"thumbnailUrl":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/home-bkg.jpg","datePublished":"2024-12-06T18:18:26+00:00","dateModified":"2026-09-15T20:18:08+00:00","breadcrumb":{"@id":"https:\/\/www.adarx.com\/dev\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adarx.com\/dev\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.adarx.com\/dev\/#primaryimage","url":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/home-bkg.jpg","contentUrl":"https:\/\/www.adarx.com\/dev\/wp-content\/uploads\/2024\/12\/home-bkg.jpg","width":3840,"height":1608,"caption":"home-bkg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.adarx.com\/dev\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.adarx.com\/dev\/"},{"@type":"ListItem","position":2,"name":"Home"}]},{"@type":"WebSite","@id":"https:\/\/www.adarx.com\/dev\/#website","url":"https:\/\/www.adarx.com\/dev\/","name":"ADARx Pharmaceuticals","description":"Providing hope for patients with intractable disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adarx.com\/dev\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/comments?post=298"}],"version-history":[{"count":35,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/298\/revisions"}],"predecessor-version":[{"id":1082,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/pages\/298\/revisions\/1082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media\/392"}],"wp:attachment":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media?parent=298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}